期刊文献+
共找到163篇文章
< 1 2 9 >
每页显示 20 50 100
Eudragit RS 30D修饰的冰片缓释微囊的制备与评价
1
作者 方淑冰 林琳 +4 位作者 邓彩怡 黄华 陈媛 高皓诗 郭波红 《广东药科大学学报》 CAS 2024年第2期83-90,共8页
目的筛选制备海藻酸钠-丙烯酸树脂冰片微囊(SA/RS 30D/BN MCs)的最佳工艺,并对微囊进行相关表征。方法采用复凝聚法制备SA/RS 30D/BN MCs,以包封率和载药量为考察指标,采用单因素法考察冰片、可溶性淀粉、Tween 80、海藻酸钠(SA)溶液、E... 目的筛选制备海藻酸钠-丙烯酸树脂冰片微囊(SA/RS 30D/BN MCs)的最佳工艺,并对微囊进行相关表征。方法采用复凝聚法制备SA/RS 30D/BN MCs,以包封率和载药量为考察指标,采用单因素法考察冰片、可溶性淀粉、Tween 80、海藻酸钠(SA)溶液、Eudragit RS 30D和CaCl2溶液的质量浓度对微囊质量的影响;在此基础上,以包封率为考察指标,通过L(934)正交试验筛选最佳处方,并对微囊的外观形态、理化性质、体外释放情况及初步稳定性进行评价。结果SA/RS 30D/BN MCs最佳处方为:冰片、可溶性淀粉、Tween 80、SA溶液、Eudragit RS 30D、CaCl2溶液的质量浓度分别为3.33%、0.17%、0.17%、1.00%、5.00%、1.50%,微囊的平均包封率为(94.18±0.47)%,平均载药量为(30.42±0.17)%,在初步稳定性试验中微囊中冰片保留率高达92.2%,表征结果表明成功制备了具有缓释性能的冰片微囊。结论采用复凝聚法以海藻酸钠、Eudragit RS 30D为复合囊材制备的冰片微囊可以显著提高冰片的稳定性且具有一定的缓释效果。 展开更多
关键词 eudragit RS 30D 海藻酸钠 冰片 复凝聚法 微囊 缓释制剂
下载PDF
Eudragit®-PEG Nanoparticles: Physicochemical Characterization and Interfacial Tension Measurements
2
作者 Papa Mady Sy Sidy Mouhamed Dieng +4 位作者 Alphonse Rodrigue Djiboune Louis Augustin Diaga Diouf Boucar Ndong Gora Mbaye Mounibé Diarra 《Open Journal of Biophysics》 2024年第2期121-131,共11页
The objectives of this study are to understand the mechanisms involved in the stabilization of water/oil interfaces by polymeric nanoparticles (NPs) (Eudragit®). Eudragit L100 NPs of various sizes and Zeta potent... The objectives of this study are to understand the mechanisms involved in the stabilization of water/oil interfaces by polymeric nanoparticles (NPs) (Eudragit®). Eudragit L100 NPs of various sizes and Zeta potentials were studied and compared at a water/cyclohexane model interface using a droplet tensiometer (Tracker Teclis, Longessaigne, France). The progressive interfacial adsorption of the NPs in the aqueous phase was monitored by tensiometry. The model interface was maintained and observed in a drop tensiometer, analyzed via axisymmetric drop shape analysis (ADSA), to determine the interfacial properties. Given the direct relationship between the stability of Pickering emulsions (emulsions stabilized by solid nanoparticles) and the interfacial properties of these layers, different nanoparticle systems were compared. Specifically, Eudragit NPs of different sizes were examined. Moreover, the reduction of the Zeta potential with PEG-6000 induces partial aggregation of the NPs (referred to as NP flocs), significantly impacting the stability of the interfacial layer. Dynamic surface tension measurements indicate a significant decrease in interfacial tension with Eudragit® nanoparticles (NPs). This reduction correlates with the size of the NPs, highlighting that this parameter does not operate in isolation. Other factors, such as the contact angle and wettability of the nanoparticles, also play a critical role. Notably, larger NPs further diminished the interfacial tension. This study enhances our understanding of the stability of Pickering emulsions stabilized by Eudragit® L100 polymeric nanoparticles. 展开更多
关键词 NANOPARTICLES eudragit® PEG Interfacial Tension Pickering Emulsion
下载PDF
极耐高温木聚糖酶的Eudragit S-100固定化及其对不同纸浆的助漂作用 被引量:4
3
作者 李里特 朱运平 +2 位作者 江正强 艾志录 李秀婷 《中国造纸》 CAS 北大核心 2005年第7期1-5,共5页
以溶解性可以通过pH值进行调节的EudragitS 1 0 0为载体,对海栖热袍菌的极耐高温木聚糖酶B(XynB)进行固定化,并对固定化酶的性质进行了测定,初步研究了固定化酶对浆料的助漂效果。结果表明,XynB经固定化后,酶活回收率高达90 % ,且对原... 以溶解性可以通过pH值进行调节的EudragitS 1 0 0为载体,对海栖热袍菌的极耐高温木聚糖酶B(XynB)进行固定化,并对固定化酶的性质进行了测定,初步研究了固定化酶对浆料的助漂效果。结果表明,XynB经固定化后,酶活回收率高达90 % ,且对原酶有纯化作用,固定化酶达到电泳单一带的纯度。固定化酶与游离酶相比,最适温度提高了5℃,达95℃,温度稳定性也有较大提高。可溶性固定化酶能有效作用于不溶底物,纸浆经固定化酶处理后释放出大量的还原糖,浆料卡伯值均有不同程度降低,表明固定化酶应用于纸浆助漂有很大潜力。 展开更多
关键词 耐高温木聚糖酶 海栖热袍菌 固定化 纸浆预漂 eudragit S-100
下载PDF
替米考星Eudragit L100纳米粒的制备及体外评价 被引量:4
4
作者 杜昌余 王洪光 +1 位作者 林卫瑞 王嘉伟 《中国抗生素杂志》 CAS CSCD 北大核心 2013年第11期848-852,共5页
目的研究Eudragit L100纳米粒的制备工艺和处方,并考察其包封率和体外释放度。方法以Eudragit L100为高分子载体材料,以替米考星为模型药物,采用溶剂非溶剂法制备纳米粒。用透射电镜观察其形态,纳米粒度仪测定其粒径分布,用透析袋法测... 目的研究Eudragit L100纳米粒的制备工艺和处方,并考察其包封率和体外释放度。方法以Eudragit L100为高分子载体材料,以替米考星为模型药物,采用溶剂非溶剂法制备纳米粒。用透射电镜观察其形态,纳米粒度仪测定其粒径分布,用透析袋法测定纳米粒的包封率,动态透析法研究其体外释放度。结果制备的纳米粒为结构致密的球体,且均匀规整,平均粒径为(45.6±4.8)nm左右。包封率为达95%以上,载药量(20.64±0.36)%。替米考星纳米粒的体外释药具有显著的pH敏感性,且具有一定的缓释效果。结论溶剂非溶剂法制备了均匀规整、包封率高、且具有一定缓释效果的替米考星纳米粒。 展开更多
关键词 替米考星 纳米粒 eudragit L100 包封率
下载PDF
Eudragit L30D-55和NE30D在软胶囊肠溶包衣中的应用 被引量:8
5
作者 韩海岭 丁宇 +2 位作者 柴佩华 陈志芳 王建新 《中国医药工业杂志》 CAS CSCD 北大核心 2008年第6期432-434,共3页
以Eudragit L30D-55为肠溶衣材料,通过加入Eudragit NE30D调整肠溶衣膜的延展性,以聚乙二醇6000为增塑剂调节最低成膜温度,通过正交试验优化了软胶囊包衣液的处方。3批肠溶软胶囊于(25±2)℃、RH(60±5)%环境放置6个月,均符合... 以Eudragit L30D-55为肠溶衣材料,通过加入Eudragit NE30D调整肠溶衣膜的延展性,以聚乙二醇6000为增塑剂调节最低成膜温度,通过正交试验优化了软胶囊包衣液的处方。3批肠溶软胶囊于(25±2)℃、RH(60±5)%环境放置6个月,均符合中国药典2005年版肠溶制剂的相关标准。 展开更多
关键词 软胶囊 肠溶包衣 eudragit L30D-55 eudragit NE30D
下载PDF
Eudragit~ NM30D在双氯芬酸钠缓释骨架片中的应用 被引量:4
6
作者 韩海岭 柴佩华 +1 位作者 丁宇 王建新 《华西药学杂志》 CAS CSCD 北大核心 2008年第4期399-401,共3页
目的研究双氯芬酸钠缓释片的处方和工艺,并了解聚合物的材料特性及释药机理。方法以聚合物Eudragit~ NM30D水分散体为缓释骨架材料和黏合剂,采用湿法造粒工艺制备双氯芬酸钠缓释骨架片。分别考察聚合物用量、填充剂种类、用量和颗粒... 目的研究双氯芬酸钠缓释片的处方和工艺,并了解聚合物的材料特性及释药机理。方法以聚合物Eudragit~ NM30D水分散体为缓释骨架材料和黏合剂,采用湿法造粒工艺制备双氯芬酸钠缓释骨架片。分别考察聚合物用量、填充剂种类、用量和颗粒大小对药物释放速率的影响。结果Eudragit~ NM30D聚合物在双氯芬酸钠缓释片中可起到缓释骨架的作用;在湿法制粒工艺中,可直接用作黏合剂制粒,简化生产过程。干聚合物的用量为10%、以乳糖为填充剂制备的双氯芬酸钠缓释片的缓释效果与市售对照制剂相似。结论Eudragit~ NM30D可用于双氯芬酸钠缓释骨架片的研制开发,且具有用量少、处方简单、工艺重复性好的特点。 展开更多
关键词 eudragit~ NM30D 缓释骨架片 双氯芬酸钠 湿法制粒
下载PDF
Eudragit L-100固定球毛壳霉菌木聚糖酶酶学性质的研究 被引量:1
7
作者 周玉恒 张厚瑞 +3 位作者 蔡爱华 向秋 何成新 方宏 《食品科学》 EI CAS CSCD 北大核心 2007年第3期198-203,共6页
采用可逆溶解性聚合物EudragitL-100对球毛壳菌木聚糖酶进行了吸附固定化。在1.0%EudragitL-100浓度时获得10.6IU/mg载体的固定化酶活和88.47%的酶活回收。酶固定化后最适温度不变,最适pH向碱性方向移动了一个pH单位。固定化酶热稳定性... 采用可逆溶解性聚合物EudragitL-100对球毛壳菌木聚糖酶进行了吸附固定化。在1.0%EudragitL-100浓度时获得10.6IU/mg载体的固定化酶活和88.47%的酶活回收。酶固定化后最适温度不变,最适pH向碱性方向移动了一个pH单位。固定化酶热稳定性和操作稳定性显著提高,循环利用6次仍保留65%初始酶活。木聚糖水解产物测定表明,在同酶用量的条件下固定化后总还原糖产量明显高于游离酶,二者水解产物均以低聚糖为主,酶固定化后水解产物木二糖含量显著高于游离酶,成为主要的产物。木聚糖酶固定化后各方面特性明显优于游离酶,在低聚糖生产中有实际应用价值。 展开更多
关键词 可逆溶解性聚合物 eudragit L-100 固定化 球毛壳霉 木聚糖酶 低聚木糖
下载PDF
EudragitS-100对蛋白折叠的促进作用 被引量:1
8
作者 黄志锋 杨树林 +2 位作者 张翼 冯文科 李校堃 《中国药科大学学报》 CAS CSCD 北大核心 2009年第3期273-278,共6页
目的:以重组人角化细胞生长因子(recombinant human keratinocyte growth factor-2,rhKGF-2)为模型,研究一种对pH较为敏感的多聚化合物聚丙烯酸树脂EudragitS-100对蛋白折叠的促进作用及其作用机制。方法:直接将变性蛋白加入到含有不同... 目的:以重组人角化细胞生长因子(recombinant human keratinocyte growth factor-2,rhKGF-2)为模型,研究一种对pH较为敏感的多聚化合物聚丙烯酸树脂EudragitS-100对蛋白折叠的促进作用及其作用机制。方法:直接将变性蛋白加入到含有不同浓度Eudragit的蛋白复性缓冲液中,采用MTT法、荧光分光光度法、圆二色光谱法以及高效液相色谱法来比较分析不同浓度EudragitS-100对变性rhKGF-2的复性促进作用。结果:在Eudragit S-100作用下,rhKGF-2的复性产率比普通稀释复性法显著增高且最高达到71%。研究表明Eudragit S-100的促进蛋白折叠的作用是基于Eudragit S-100与rh-KGF-2发生了特异性的结合反应。另外,本研究还发现蛋白复性缓冲液中尿素的浓度对蛋白的复性也存在较大影响。结论:Eudragit S-100能显著提高以rhKGF-2为代表的蛋白的正确折叠和复性收率。 展开更多
关键词 聚丙烯酸树脂eudragit S-100 重组人角化细胞生长因子-2(rhKGF-2) 蛋白折叠
下载PDF
可溶可逆聚合物Eudragit S-100对猪胰脂肪酶的固定化
9
作者 袁久刚 申璇 +4 位作者 张庆娟 余圆圆 王平 王强 范雪荣 《食品与生物技术学报》 CAS CSCD 北大核心 2018年第2期179-184,共6页
为了降低不溶性载体固定化对酶催化效率和回收利用的影响,本文作者采用智能性聚合物Eudragit S-100对猪胰脂肪酶进行了固定化修饰。Eudragit S-100主要由甲基丙烯酸和甲基丙烯酸甲酯共聚而成,具备p H响应的可溶可逆性。结果显示:活化后... 为了降低不溶性载体固定化对酶催化效率和回收利用的影响,本文作者采用智能性聚合物Eudragit S-100对猪胰脂肪酶进行了固定化修饰。Eudragit S-100主要由甲基丙烯酸和甲基丙烯酸甲酯共聚而成,具备p H响应的可溶可逆性。结果显示:活化后的Eudragit S-100树脂能够与脂肪酶进行共价结合,在15℃条件下反应6 h后,脂肪酶的平均氨基修饰率约为52.4%;荧光光谱测试表明固定化修饰使得脂肪酶分子肽链发生了一定折叠,脂肪酶的结构较修饰前更为紧凑。固定化后脂肪酶的最适温度保持不变,最适p H向碱性方向移动,总体上表现出更好的稳定性。此外,固定化脂肪酶具备p H响应的可溶可逆性,能够重复使用,经过5次重复使用后,酶活保留仍有45%左右。 展开更多
关键词 猪胰脂肪酶 可溶可逆 eudragitS-100 固定化
下载PDF
Influence of Preparation Factors on the Sustained Release of Nifedipine from Eudragit RL/RS Microspheres 被引量:1
10
作者 傅崇东 蒋雪涛 +1 位作者 胡晋红 张万国 《Journal of Chinese Pharmaceutical Sciences》 CAS 1997年第4期31-38,共8页
Sustained release Eudragit RL/RS microspheres encapsulating nifedipine were prepared using the acetone/liquid paraffin emulsion solvent evaporation method. The influence of different preparation factors on release o... Sustained release Eudragit RL/RS microspheres encapsulating nifedipine were prepared using the acetone/liquid paraffin emulsion solvent evaporation method. The influence of different preparation factors on release of the drug in vitro was investigated. The release rate of nifedipine from the microspheres increased with increasing Eudragit RL/RS ratio and stirring rate during the preparation, and with decreasing the polymer concentration of internal phase and microsphere size. It was found that a linear relationship existed between the microsphere size and the time of 50% drug release. The drug release rate increased with increasing nifedipine content from 4.2 to 16.7% and was more rapid than the dissolution rate of pure nifedipine particles. However, the release rate of the microspheres with 26.6% drug content decreased significantly and was slower than the dissolution rate of pure drug particles. This was attributed mainly to the nifedipine dispersion state in the microspheres as confirmed by the differential thermal analysis and X ray diffraction study, which showed that nifedipine was present in an amorphous or molecular state in the microspheres with 4.2, 9.4 and 16.7% drug, whereas partly in the crystalline state in the microspheres with 26.6% drug. The amounts released for less than 70% nifedipine can be fitted to Higuchi square root of time model, independent of polymer ratio, drug content and microsphere size. 展开更多
关键词 Sustained release microspheres NIFEDIPINE eudragit RL/RS Release rate
全文增补中
索拉非尼-Eudragit RS纳米粒的制备及理化性质研究 被引量:2
11
作者 贾炜 张洪 张英 《中国药师》 CAS 2015年第4期541-544,554,共5页
目的:制备索拉非尼-Eudragit RS纳米粒(sorafenib-Eudragit RS nanoparticles,S-E NPs),优选制备处方及初步探索其理化性质。方法:溶剂-非溶剂法制备索拉非尼-Eudragit RS纳米粒,采用单因素试验研究溶剂、稳定剂类型、载体比例、有机相... 目的:制备索拉非尼-Eudragit RS纳米粒(sorafenib-Eudragit RS nanoparticles,S-E NPs),优选制备处方及初步探索其理化性质。方法:溶剂-非溶剂法制备索拉非尼-Eudragit RS纳米粒,采用单因素试验研究溶剂、稳定剂类型、载体比例、有机相水相比例对纳米粒理化性质的影响。通过粒径和Zeta电位、形貌观察、体外释药考察对其进行质量评价。结果:优选处方制备的索拉非尼-Eudragit RS纳米粒的平均粒径为(86.72±3.71)nm,多相分散系数(PDI)为(0.200±0.032),Zeta电位为(36.6±0.3)m V,纳米粒呈球形且分布均匀;体外释放符合Weibull模型(r=0.966 9)。结论:溶剂-非溶剂法适用于索拉非尼-Eudragit RS纳米粒的制备,所制备的纳米粒粒径较小,分布均匀,形态规则完整,具有明显缓释作用。 展开更多
关键词 索拉非尼 eudragit RS100 纳米粒 溶剂-非溶剂法 优化 体外释放
下载PDF
海藻酸钠改善Eudragit RS 30 D游离膜老化及其机制研究 被引量:3
12
作者 黄权华 杨璐 +2 位作者 张杰 杨星钢 杨战鏖 《中南药学》 CAS 2020年第5期721-726,共6页
目的考察海藻酸钠(SA)改善尤特奇RS 30 D(Eudragit RS 30 D)包衣膜的性质并验证其机制。方法采用zeta电位、热重分析仪(TGA)、差示扫描量热仪(DSC)等表征手段对Eudragit RS 30 D-SA游离膜性质进行了考察,通过Eudragit RS 30 D-SA游离膜... 目的考察海藻酸钠(SA)改善尤特奇RS 30 D(Eudragit RS 30 D)包衣膜的性质并验证其机制。方法采用zeta电位、热重分析仪(TGA)、差示扫描量热仪(DSC)等表征手段对Eudragit RS 30 D-SA游离膜性质进行了考察,通过Eudragit RS 30 D-SA游离膜老化前后吸水溶胀性、水蒸气透过率、机械性能进行初步验证。结果Zeta电位显示加入SA溶液,Eudragit RS 30 D水分散体的zeta电位逐渐降低,且TGA、DSC等表征结果显示,Eudragit RS 30 D-SA游离膜的含水量明显高于Eudragit RS 30 D游离膜。Eudragit RS 30 D与SA间的静电相互作用和SA的“保水”能力是SA解决丙烯酸树脂类水分散体老化问题的重要机制。Eudragit RS 30 D-SA包衣膜在多个方面具备一定优势。结论SA可以改善Eudragit RS 30 D游离膜的性质,改善Eudragit RS 30 D游离膜老化问题,使其在多个方面均具有一定优势。 展开更多
关键词 eudragit RS 30 D 海藻酸钠 性质 老化 机制
下载PDF
阳离子聚合物Eudragit RL对电解质的敏感性及其对不同药物释放的影响 被引量:2
13
作者 傅崇东 赵磊 蒋雪涛 《药学学报》 CAS CSCD 北大核心 1998年第7期538-543,共6页
研究聚合物EudragitRL在电解质溶液中的膨胀行为,以及介质组成及聚合物膨胀度对硝苯地平、氯苯那敏(扑尔敏)和吲哚美辛从聚合物骨架中释放的影响。用转篮法及浆板法测定微球和药膜的释放度。结果表明EudragitRL... 研究聚合物EudragitRL在电解质溶液中的膨胀行为,以及介质组成及聚合物膨胀度对硝苯地平、氯苯那敏(扑尔敏)和吲哚美辛从聚合物骨架中释放的影响。用转篮法及浆板法测定微球和药膜的释放度。结果表明EudragitRL的膨胀度随电解质浓度增加而下降,且受电解质种类的影响显著。硝苯地平和氯苯那敏从聚合物骨架中的释放速率与聚合物膨胀行为间呈良好正相关,但吲哚美辛从聚合物中的释放速率受聚合物膨胀和离子对药物的置换两种因素同时控制。提示EudragitRL骨架中药物的释放方式受介质组成和药物种类的影响。 展开更多
关键词 阳离子型 丙烯酸树脂 药物释放 硝苯地平
下载PDF
盐酸小檗碱-Eudragit S100固体分散体的制备及评价 被引量:4
14
作者 王冠华 王金悦 +3 位作者 黄金 吴桐 单新竹 张向荣 《沈阳药科大学学报》 CAS CSCD 北大核心 2019年第1期1-6,共6页
目的选用具有pH敏感性的Eudragit~? S100 (S100)作为载体材料制备盐酸小檗碱(berberine hydrochloride,HB)-S100固体分散体,达到延迟药物释放的目的。方法采用溶剂挥发法制备HB-S100肠溶固体分散体,并通过体外溶出实验筛选出符合实验目... 目的选用具有pH敏感性的Eudragit~? S100 (S100)作为载体材料制备盐酸小檗碱(berberine hydrochloride,HB)-S100固体分散体,达到延迟药物释放的目的。方法采用溶剂挥发法制备HB-S100肠溶固体分散体,并通过体外溶出实验筛选出符合实验目的的HB和S100的处方比例。利用XRD技术考察HB-S100相关的理化性质。结果 HB和Eudragit~?S100的处方质量比为1∶4,所形成的固体分散体盐酸小檗碱呈不定形状态。结论将HB与S100制备成固体分散体可以达到缓释的效果,同时为进一步开发HB的新剂型提供了基础。 展开更多
关键词 盐酸小檗碱 eudragit S100 固体分散体 缓释
下载PDF
Preparation and characterization of spray-dried valsartan-loaded Eudragit~? EPO solid dispersion microparticles 被引量:3
15
作者 Roshan Pradhan Sung Yub Kim +1 位作者 Chul Soon Yong Jong Oh Kim 《Asian Journal of Pharmaceutical Sciences》 SCIE CAS 2016年第6期744-750,共7页
The purpose of this study was to develop the immediate release stomach-specific spraydried formulation of valsartan(VAL) using Eudragit?E PO(EPO) as the carrier for enhancing dissolution rate in a gastric environment.... The purpose of this study was to develop the immediate release stomach-specific spraydried formulation of valsartan(VAL) using Eudragit?E PO(EPO) as the carrier for enhancing dissolution rate in a gastric environment. Enhanced solubility and dissolution in gastric pH was achieved by formulating the solid dispersion using a spray drying technique. Different combinations of drug–polymer–surfactant were dissolved in 10% ethanol solution and spraydried in order to obtain solid dispersion microparticles. Use of the VAL–EPO solid dispersion microparticles resulted in significant improvement of the dissolution rate of the drug at pH 1.2 and pH 4.0, compared to the free drug powder and the commercial product. A hard gelatin capsule was filled with the VAL–EPO solid dispersion powder prior to the dissolution test.The increased dissolution of VAL from solid dispersion microparticles in gastric pH was attributed to the effect of EPO and most importantly the transformation of crystalline drugs to amorphous solid dispersion powder, which was clearly shown by scanning electron microscopy(SEM), differential scanning calorimetry(DSC), and powder X-ray diffraction(PXRD) studies. Thus, VAL, a potential antihypertensive drug in the form of a solid dispersion microparticulate powder, can be effectively delivered in the immediate release dosage form for stomach-specific drug delivery. 展开更多
关键词 VALSARTAN eudragit E PO Solubility Solid dispersion SPRAY-DRYING
下载PDF
A stepwise optimization strategy to formulate in situ gelling formulations comprising fluconazole-hydroxypropyl-beta-cyclodextrin complex loaded niosomal vesicles and Eudragit nanoparticles for enhanced antifungal activity and prolonged ocular delivery 被引量:2
16
作者 Heba Elmotasem Ghada E.A.Awad 《Asian Journal of Pharmaceutical Sciences》 SCIE CAS 2020年第5期617-636,共20页
Fungal keratitis and endopthalmitis are serious eye diseases.Fluconazole(FL)is indicated for their treatment,but suffers from poor topical ocular availability.This study was intended to improve and prolong its ocular ... Fungal keratitis and endopthalmitis are serious eye diseases.Fluconazole(FL)is indicated for their treatment,but suffers from poor topical ocular availability.This study was intended to improve and prolong its ocular availability.FL niosomal vesicles were prepared using span 60.Also,polymeric nanoparticles were prepared using cationic Eudragit RS100 and Eudragit RL100.The investigated particles had adequate entrapment efficiency(EE%),nanoscale particle size and high zeta potential.Subsequently,formulations were optimized using full factorial design.FL-HP-β-CD complex was encapsulated in selected Eudragit nanoprticles(FL-CD-ERS1)and niosmal vesicles.The niosomes were further coated with cationic and bioadhesive chitosan(FL-CD-Nios-ch).EE%for FL-CD-ERS1 and FL-CD-Niosch formulations were 76.4%and 61.7%;particle sizes were 151.1 and 392 nm;also,they exhibited satisfactory zeta potential+40.1 and+28.5 m V.In situ gels were prepared by poloxamer P407,HPMC and chitosan and evaluated for gelling capacity,rheological behavior and gelling temperature.To increase the precorneal residence time,free drug and selected nano-formulations were incorporated in the selected in situ gel.Release study revealed sustained release within 24 h.Permeation through excised rabbits corneas demonstrated enhanced drug flux and large AUC0-6 h in comparison to plain drug.Corneal permeation of selected formulations labeled with Rhodamine B was visualized by Confocal laser microscopy.Histopathological study and in vivo tolerance test evidenced safety.In vivo susceptibility test using Candida albicans depicted enhanced growth inhibition and sustained effect.In this study the adopted stepwise optimization strategy combined cylodextrin complexation,drug nano-encapsulation and loading within thermosenstive in situ gel.Finally,the developed innovated formulations displayed boosted corneal permeation,enhanced antifungal activity and prolonged action. 展开更多
关键词 FLUCONAZOLE Ocular eudragit nanoparticles CYCLODEXTRIN NIOSOMES In situ gel
下载PDF
Role of clove oil in solvent exchange-induced doxycycline hyclate-loaded Eudragit RS in situ forming gel 被引量:1
17
作者 Thawatchai Phaechamud Sai Myo Thurein Takron Chantadee 《Asian Journal of Pharmaceutical Sciences》 SCIE CAS 2018年第2期131-142,共12页
Solvent exchange induced in situ forming gel(ISG) is the promising drug delivery system for periodontitis treatment owing to the prospect of maintaining an effective high drug level in the gingival crevicular fluid. I... Solvent exchange induced in situ forming gel(ISG) is the promising drug delivery system for periodontitis treatment owing to the prospect of maintaining an effective high drug level in the gingival crevicular fluid. In the present study, the influence of clove oil(CO) on the characteristics of doxycycline hyclate(DH)-loaded ISG comprising Eudragit RS(ERS) was investigated including viscosity/rheology, syringeability, in vitro gel formation/drug release, matrix formation/solvent diffusion and antimicrobial activities. CO could dissolve ERS and increase the viscosity of ISG and its hydrophobicity could also retard the diffusion of solvent and hinder the drug diffusion; thus, the minimization of burst effect and sustained drug release were achieved effectively. All the prepared ISGs comprising CO could expel through the 27-gauge needle for administration by injection and transform into matrix depot after exposure to the simulated gingival crevicular fluid. The antimicrobial activities against Staphylococcus aureus, Escherichia coli, Streptococcus mutans and Porphyromonas gingivalis were increased when the ratio of CO and N-methyl pyrrolidone(NMP) was decreased from 1:1 to 1:10 owing to higher diffusion of DH except that for C. albicans was increased as CO amount was higher.Therefore, CO could minimize the burst while prolonging the drug release of DH-loaded ERS ISG for use as a local drug delivery system for periodontitis treatment. 展开更多
关键词 In SITU FORMING GEL eudragit RS CLOVE oil DOXYCYCLINE hyclate Periodonditis Burst release
下载PDF
Evaluation of blank film forming polymeric dispersions based on Eudragit RL 30D and RS30D for transdermal drug delivery 被引量:1
18
作者 Chaowalit Monton Jirapornchai Suksaeree 《Asian Journal of Pharmaceutical Sciences》 SCIE CAS 2016年第1期100-101,共2页
The first approved transdermal drug delivery system in the United States in 1979 is a scopolamine patch for treatment of motion sickness. Transdermal drug delivery system has many advantages over oral route such as it... The first approved transdermal drug delivery system in the United States in 1979 is a scopolamine patch for treatment of motion sickness. Transdermal drug delivery system has many advantages over oral route such as it is useful for vomiting and unconscious patients. It can avoid first pass metabolism by the liver. It is non-invasive way and self-administered system compared to injections. The film forming polymeric solutions are a novel transdermal drug delivery system. This system consists of an active drug, film forming polymer, plasticizer. 展开更多
关键词 Film forming POLYMERIC DISPERSIONS eudragit TRANSDERMAL DRUG delivery
下载PDF
Eudragit L-100固定β-葡萄糖苷酶的性能研究
19
作者 燕杰善 秦瑞霞 李露 《化工科技》 CAS 2018年第3期5-10,共6页
以Eudragit L-100(E)为载体,对β-葡萄糖苷酶(CB)进行固定化修饰,考察了各种因素对固定化酶活力收率的影响。并使用红外光谱、圆二色谱及荧光光谱对固定化产物进行表征。结果表明,酶的较佳固定化条件为pH=11.0,w(E)=1%,ρ(CB)=2mg/mL,... 以Eudragit L-100(E)为载体,对β-葡萄糖苷酶(CB)进行固定化修饰,考察了各种因素对固定化酶活力收率的影响。并使用红外光谱、圆二色谱及荧光光谱对固定化产物进行表征。结果表明,酶的较佳固定化条件为pH=11.0,w(E)=1%,ρ(CB)=2mg/mL,固定时间60min,沉淀时间30min,固定化温度25℃,固定化酶活力收率为83%。固定化酶溶解度的变化条件为pH>5.2时呈可溶性,pH<4.5时呈不溶性。固定化酶的热稳定性有了一定的提高,并且固定化酶重复利用5次后仍保留41%的初始酶活力。 展开更多
关键词 eudragit L-100 Β-葡萄糖苷酶 热稳定性 重复利用
下载PDF
EudragitS100与HPMC在茶碱缓释片中的应用比较与研究
20
作者 孙善贞 丛培红 《山东医药工业》 2000年第4期44-45,共2页
EudragitS100(又称优特奇S100)是一完全人工合成的聚甲基丙烯酸酯系列聚合物之一。它具有在pH>7的环境下溶出的特性,因而可用于肠道一定位释放的肠溶包衣材料。另外,利用聚甲基丙烯酸酯制备口服制剂骨架片近来也得到应用,本文就把Eu-... EudragitS100(又称优特奇S100)是一完全人工合成的聚甲基丙烯酸酯系列聚合物之一。它具有在pH>7的环境下溶出的特性,因而可用于肠道一定位释放的肠溶包衣材料。另外,利用聚甲基丙烯酸酯制备口服制剂骨架片近来也得到应用,本文就把Eu-dragitS100与HPMC在茶碱缓释片中的应用作一下比较: 展开更多
关键词 茶碱缓释片 eudragitS100 HPMC
下载PDF
上一页 1 2 9 下一页 到第
使用帮助 返回顶部